Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | PTGER3 | P43115 | 3/20 | 0.42 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.42 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.42 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.38 |
| ▸ | FABP3 | P05413 | 2/20 | 0.38 |
| ▸ | FABP4 | P15090 | 2/20 | 0.38 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.38 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035132 | 1.00 | KDM4E (0.44) | KDM4EALDH1A1PKMPTGER3PTGER1 | |
| SCHEMBL6036020 | 0.80 | LMNA (0.43) | ALDH1A1LMNAHRH3SGMS2KCNJ6 | |
| SCHEMBL6035432 | 0.79 | PKM (0.52) | KDM4EALDH1A1PKMPTGER3PTGER1 | |
| SCHEMBL6035428 | 0.79 | PKM (0.52) | KDM4EALDH1A1PKMPTGER3PTGER1 | |
| SCHEMBL6035636 | 0.78 | HRH3 (0.43) | HRH3SGMS2FABP3FABP4KCNJ6 | |
| SCHEMBL5405463 | 0.78 | ALDH1A1 (0.48) | KDM4EALDH1A1PKMPTGER3PTGER1 | |
| SCHEMBL5405458 | 0.78 | ALDH1A1 (0.48) | KDM4EALDH1A1PKMPTGER3PTGER1 | |
| SCHEMBL5113563 | 0.78 | PKM (0.48) | KDM4EALDH1A1PKMPTGER3PTGER1 | |
| SCHEMBL5113557 | 0.78 | PKM (0.48) | KDM4EALDH1A1PKMPTGER3PTGER1 | |
| SCHEMBL5107853 | 0.77 | KDM4E (0.48) | KDM4EALDH1A1PKMPTGER3PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | KDM4E 509/4885ALDH1A1 1442/4885PKM 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.